Cargando…
Rapamycin Monotherapy in Patients With Type 1 Diabetes Modifies CD4(+)CD25(+)FOXP3(+) Regulatory T-Cells
OBJECTIVE—Rapamycin is an immunosuppressive drug currently used to prevent graft rejection in humans, which is considered permissive for tolerance induction. Rapamycin allows expansion of both murine and human naturally occurring CD4(+)CD25(+)FOXP3(+) T regulatory cells (nTregs), which are pivotal f...
Autores principales: | Monti, Paolo, Scirpoli, Miriam, Maffi, Paola, Piemonti, Lorenzo, Secchi, Antonio, Bonifacio, Ezio, Roncarolo, Maria-Grazia, Battaglia, Manuela |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2518485/ https://www.ncbi.nlm.nih.gov/pubmed/18559659 http://dx.doi.org/10.2337/db08-0138 |
Ejemplares similares
-
Expansion of Th17 Cells and Functional Defects in T Regulatory Cells Are Key Features of the Pancreatic Lymph Nodes in Patients With Type 1 Diabetes
por: Ferraro, Alessandra, et al.
Publicado: (2011) -
WASP regulates suppressor activity of human and murine CD4(+)CD25(+)FOXP3(+) natural regulatory T cells
por: Marangoni, Francesco, et al.
Publicado: (2007) -
Uncoupling of Proliferation and Cytokines From Suppression Within the CD4+CD25+Foxp3+ T–Cell Compartment in the 1st Year of Human Type 1 Diabetes
por: Hughson, Angela, et al.
Publicado: (2011) -
Rapamycin Prevents and Breaks the Anti-CD3–Induced Tolerance in NOD Mice
por: Valle, Andrea, et al.
Publicado: (2009) -
Anti-CD25 radioimmunotherapy with BEAM autologous hematopoietic cell transplantation conditioning in Hodgkin lymphoma
por: Herrera, Alex F., et al.
Publicado: (2021)